Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
about
Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cellsEnzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.Prognostic molecular markers in early breast cancerThe urokinase plasminogen activator system as a target for prognostic studies in breast cancer.The plasmin cascade and matrix metalloproteinases in non-small cell lung cancerUrokinase plasminogen activator: a prognostic marker in multiple types of cancer.Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesismicroRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.Proteolysis in human breast cancer.Can axillary dissection be avoided by improved molecular biological diagnosis?The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.Node-Negative Breast Cancer: Which Patients Should Be Treated?Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator SystemuPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.Chemical strategies for activity-based proteomics.Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.Organ Specific Tumor Markers: What's New?Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasisExternal quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extractsDevelopment of a new metastatic human breast carcinoma xenograft line.Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods.Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cellsContribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancerPlasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.Plasminogen activator inhibitor type 2 in breast cancer.Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factorsDifferential regulation of cell proliferation and protease secretion by epidermal growth factor and amphiregulin in tumoral versus normal breast epithelial cellsInhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1.Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.Revisiting the biological roles of PAI2 (SERPINB2) in cancer.Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.Genetic alterations in breast cancer.Nutrition and breast cancer risk: can an effect via insulin resistance be demonstrated?The biochemistry of cancer dissemination.Proteolysis in human breast and colorectal cancer.
P2860
Q22009110-81DE8FA1-0226-49D8-860C-DAF3AC3D1539Q24533487-510E9F9E-6C2B-4B54-9B67-A221A4FC5E79Q24794845-C6BB1E42-6D3F-4B8C-B380-6AAF5EE00E10Q33538432-08971082-ED0D-4DDE-B338-1A7A5D77FA4FQ33634208-E5FC76F7-5CC9-4E1E-B89D-BD56162ECFBAQ33676610-01A0135E-2258-4A59-BD93-E29118F45C17Q33743421-736692C9-9A4C-48CB-BA9B-EC2E31632B85Q33779244-6D61FDF3-8607-4AFC-B8D8-3C8FA76CFE55Q33918458-E6213EDD-694B-40FA-9583-75EE384286C0Q34033291-C9CFE1A4-AC7E-49D5-8899-D5EE73642847Q34165118-66188CF9-956D-4798-9DBB-B3F65E456B8EQ34284270-8022225D-F90D-40C0-ABB0-185788B7FCA2Q35495620-160BE806-9056-4645-A9BA-366562BA2EADQ35580701-113F378B-0C2B-4F04-9E97-E548F3543285Q35616321-B0BD0672-0DD4-4E49-8BD2-2432E38C16CDQ35745390-EDF13B1E-D392-4878-B09E-F74883EDD97FQ35980584-2BAEF044-9688-4AB5-AB20-DF55B6A2C118Q36114916-1224A880-7DEE-492A-8314-C047A437AA85Q36115751-756135DA-40DD-4B94-8646-516A746DEDDAQ36291662-6E87F3E5-60FD-4CBA-A9E2-99ADA9AD30EBQ36292147-792B8C1D-B67D-4D7B-B0EE-982713E5D204Q36292537-81492B6A-FA5B-4EDE-A9C8-AB2104A55357Q36295115-6CE4E06F-85D2-490F-894E-6CA71781416DQ36421968-975E23A1-09AC-4DD3-A31E-1FE4C9003290Q36430945-5E0CDA14-707C-42B0-8018-431794F05401Q36430997-0F9F7BC6-31CD-4270-9F00-9A51920C2FFCQ36617844-9CF9A6A6-46DC-4D35-979B-8FFF2934A7FEQ36617900-696BC215-FFAB-4DE7-A1E0-71FF825FCE76Q36620181-ABC7CF94-C06C-42C7-B1B9-0EEB820ECBF5Q36622861-01A8FFB1-5D97-4224-BB0E-A61D0E1F0144Q36641395-5EDC1F9E-B7A2-4AAE-9F7D-F29C03471C69Q36840119-5FAC2E68-421C-4325-B14D-1CDF6AD05438Q37189305-A4102E05-19F3-4211-BFB5-4DD4BF430E98Q37203214-4D29B9FC-C756-429D-8688-6DF55CEBC868Q39712414-FC07D90F-9D8E-4AD4-86C0-C6259F570431Q40573725-6F82693C-2A90-4FB5-8FB5-800C3F498D72Q40972502-135B92DF-2E73-41F0-A6FD-317563E962A4Q41062519-8FAC939D-E400-4C06-A7AB-B12AAE3B92A6Q41547351-36A741E6-F7D2-4BC4-BE17-0AEF91ACEF95Q42095382-E3E75E9B-28B6-4E3A-AB13-5CAAA9A1DB9F
P2860
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@ast
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@en
type
label
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@ast
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@en
prefLabel
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@ast
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@en
P2093
P2860
P356
P1476
Prognostic value of urokinase- ...... and PAI-2 in breast carcinomas
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1994.74
P407
P577
1994-02-01T00:00:00Z